Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine
NCT: NCT07223008 · RECRUITING
Brief Summary
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Frequently Asked Questions
What is Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine?
Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine is a clinical trial registered under NCT07223008. Current status: RECRUITING.
What is the status of NCT07223008?
The current status of NCT07223008 (Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine) is: RECRUITING.
When did Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine start?
Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine started on 2026-04-24.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.